Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NOX-E36 - A Phase I, Double-Blind, Placebo Controlled, Single Intravenous and Subcutaneous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects

NCT00976729 is registered in ClinicalTrials.gov with TME Pharma AG as lead sponsor.

NCT NCT00976729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00976729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NOX-E36 - A Phase I, Double-Blind, Placebo Controlled, Single Intravenous and Subcutaneous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects
Lead sponsor
TME Pharma AG
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2009
Completion date
December 31, 2009
Enrollment
72 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic inflammatory diseases, systemic lupus erythematosus, type 2 diabetes mellitus